Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study
J M Huguet, V. García, Lidia Martí, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2130-2130
Open Access | Times Cited: 20

Showing 20 citing articles:

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 919-933
Open Access | Times Cited: 10
Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease
Jaakko Rautakorpi, Sara Kolehmainen, Eliisa Löyttyniemi, et al.
Digestive Diseases and Sciences (2025)
Open Access
Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
John David Chetwood, Yvonne Tran, Sreedhar Subramanian, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 9, pp. 1440-1449
Closed Access | Times Cited: 4
Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies
Antonio Tursi, Giammarco Mocci, Angelo Del Gaudio, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 171-189
Closed Access | Times Cited: 3
Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial
Stefan Schreiber, Geert R. D’Haens, Fraser Cummings, et al.
Digestive and Liver Disease (2024) Vol. 56, Iss. 7, pp. 1204-1212
Open Access | Times Cited: 3
Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study
Anthony Buisson, Maria Nachury, M Bazoge, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 4, pp. 526-534
Closed Access | Times Cited: 8
Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
Philip J Smith, Mathurin Fuméry, Rupert W. Leong, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 9, pp. 1143-1156
Open Access | Times Cited: 7
Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
Karin Cerna, Dana Ďuricová, Martin Lukás, et al.
Crohn s & Colitis 360 (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 7
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
Ferdinando D’Amico, Luca Massimino, Giulia Palmieri, et al.
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 11
Open Access | Times Cited: 2
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial
Robert D. Little, Jo McKenzie, Ashish Srinivasan, et al.
BMJ Open (2024) Vol. 14, Iss. 7, pp. e081787-e081787
Open Access | Times Cited: 1
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry
Marisa Iborra, Berta Caballol, Alejandro Garrido, et al.
Journal of Crohn s and Colitis (2024)
Closed Access | Times Cited: 1
Editorial: Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Giovanni Pallio
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2466-2466
Open Access | Times Cited: 3
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Bo‐In Lee, Minjee Kim, Eun Ran Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
A Comparison of Intravenous Infliximab versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, et al.
Gastro Hep Advances (2024) Vol. 4, Iss. 3, pp. 100588-100588
Open Access
A Practical Approach to Subcutaneous Infliximab (Zymfentra)
Jennifer Aoto, Benjamin Click
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 11, pp. 2151-2159
Closed Access
From Intravenous to Subcutaneous Infliximab: the Same but Different? Real-World Evidence from a Tertiary Center
María José Temido, Andréa Silva, Sandra Lópes, et al.
Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana (2024) Vol. 54, Iss. 1, pp. 56-54
Open Access
Subcutaneous versus intravenous infliximab therapy – a real-world study: toward higher drug concentrations
Ana Isabel Ferreira, Tiago Lima Capela, Cátia Arieira, et al.
European Journal of Gastroenterology & Hepatology (2024) Vol. 36, Iss. 11, pp. 1314-1318
Closed Access
Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases
Alexander T. Elford, Rishni Heldt, Shahed Kamal, et al.
European Journal of Gastroenterology & Hepatology (2024)
Closed Access
12th EHSF Conference 2023 Extended Abstracts
Sexual health and a positive body image are important aspects of quality of life that can be …, or long-term, auto-inflammatory skin disease that affects intimate areas of the body, et al.
Experimental Dermatology (2023) Vol. 32, Iss. S1, pp. 9-156
Closed Access | Times Cited: 1
Therapeutic potential of infliximab for pruritus in mice model of cholestasis induced by bile duct ligation: Possible involvement of IL-31
Zahra Soltani, Mohammad Elahi, M. Khavandi, et al.
International Immunopharmacology (2023) Vol. 123, pp. 110806-110806
Closed Access
Page 1

Scroll to top